Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children.

Clin Exp Pediatr · 2025 · PMC12488281 · PMID 40907578

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

RSV-related treatment costs per patient according to the year showed an increasing trend: $818 (95% confidence interval [CI], $799–$923) in 2017, $1,288 (95% CI, $1,196–$1,381) in 2018, $1,409 (95% CI, $1,274–$1,545) in 2019, $1,908 (95% CI, $1,611–$2,204) in 2020, and $3,338 (95% CI, $889–$5,787) in 2021.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.